# CJC-1295 references — primary sources for every claim on this site

> Full citation list for the CJC-1295 research record summarized on this site: PubMed-indexed studies, ClinicalTrials.gov registry entries, FDA Pharmacy Compounding Advisory Committee briefings, and the WADA Prohibited List.

## Primary literature and regulatory sources

The numbered references below cover every claim cited on this site. PubMed and PMC links are preferred where available; ClinicalTrials.gov links are used for trial-registry entries; the FDA briefing-materials PDFs and the WADA Prohibited List are linked directly to their official locations.

The full citation list is rendered in the references_index field of this content document; the assembler will format it as a numbered list with each entry showing the citation, the DOI (where available), and a hyperlink to the primary source.

## Editorial sourcing standards

Every quantitative claim on this site — half-life numbers, dose values, percentage elevations, trial sample sizes, study durations, adverse event frequencies, and regulatory determinations — traces to a numbered reference below. Where the published literature is ambiguous or incomplete, the site says so rather than filling the gap with secondary or non-peer-reviewed sources.

The site does not cite anonymous forum threads, vendor product pages, research-chemical-channel marketing material, or undated YouTube content. The Van Hout 2016 netnographic analysis [10] is cited because it is a peer-reviewed academic study of online forum behavior, not because the forum content itself is treated as evidence.

Where a primary source is paywalled and a freely accessible companion (PMC version, preprint, or open-access regulatory document) exists, the open version is linked.

Claims about FDA status reference the official FDA Pharmacy Compounding Advisory Committee briefing materials [14][15], not secondary summaries. Claims about WADA status reference the official 2025 Prohibited List [16] directly.

## References

[1] Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286 — https://pubmed.ncbi.nlm.nih.gov/15817669/
[2] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 — https://pubmed.ncbi.nlm.nih.gov/16352683/
[3] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Plasma half-life characterization of CJC-1295 across single- and multi-dose cohorts (mean t½ 5.8-8.1 days). Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 — https://pubmed.ncbi.nlm.nih.gov/16352683/
[4] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. doi:10.1210/jc.2006-0689 — https://pubmed.ncbi.nlm.nih.gov/17018654/
[5] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006 — https://pubmed.ncbi.nlm.nih.gov/16822960/
[6] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001 — https://pubmed.ncbi.nlm.nih.gov/19386527/
[7] ConjuChem Biotechnologies Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov identifier NCT00267527. Trial terminated October 2006. — https://clinicaltrials.gov/study/NCT00267527
[8] Jetté L, Léger R, Thibaudeau K, et al. Modified GRF(1-29) and the protective amino acid substitutions D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷ — non-DAC variant pharmacokinetics. Characterized in the same Endocrinology 2005 paper as the bioconjugate discovery. doi:10.1210/en.2004-1286 — https://pubmed.ncbi.nlm.nih.gov/15817669/
[9] Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Combined administration of GHRH and GHRP-6 acts in synergy on growth hormone (GH) release in humans. Journal of Clinical Endocrinology and Metabolism. 1990;70(4):975-982. doi:10.1210/jcem-70-4-975 — https://pubmed.ncbi.nlm.nih.gov/2107173/
[10] Van Hout MC, Hearne E. Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions. Substance Use & Misuse. 2016;51(1):73-84. doi:10.3109/10826084.2015.1082595 — https://pubmed.ncbi.nlm.nih.gov/26771670/
[11] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010;2(11-12):647-650. doi:10.1002/dta.233 — https://pubmed.ncbi.nlm.nih.gov/21204297/
[12] Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fußhöller G, Görgens C, Geyer H, Thevis M. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. Journal of Mass Spectrometry. 2024;59(2):e4996. doi:10.1002/jms.4996 — https://pubmed.ncbi.nlm.nih.gov/38197510/
[13] Steiger A, Guldner J, Hemmeter U, et al. Growth hormone-releasing hormone (GHRH) and sleep regulation. Psychoneuroendocrinology. 1992;17(2-3):125-137. doi:10.1016/0306-4530(92)90017-3 — https://pubmed.ncbi.nlm.nih.gov/1438644/
[14] U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee — CJC-1295 briefing materials. FDA docket FDA-2024-N-4777. — https://www.fda.gov/media/182088/download
[15] U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee meeting — follow-up briefing on GH secretagogue peptides. FDA docket FDA-2024-N-4777 follow-up. — https://www.fda.gov/media/183819/download
[16] World Anti-Doping Agency. World Anti-Doping Code International Standard — The 2025 Prohibited List. Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. — https://www.wada-ama.org/en/prohibited-list
[17] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8688 — https://pubmed.ncbi.nlm.nih.gov/25027139/
[18] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Adverse-event profile in the Phase 1 single- and multi-dose CJC-1295 cohorts: predominantly local injection-site reactions; systemic adverse events uncommon at 30-60 μg/kg. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 — https://pubmed.ncbi.nlm.nih.gov/16352683/

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.